secwatch.observer — SEC 8-K summary
======================================

Issuer:     DURECT CORP (—)
CIK:        0001082038
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058675
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DURECT reports Q1 net loss $7.6M; FDA supports single pivotal trial for larsucosterol in AH
--------------------------------------------------------------------------------

- FDA feedback supports single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis; NDA filing possible if successful.
- Q1 2024 total revenues $1.8M, net loss $7.6M vs revenues $2.1M, net loss $12.0M in Q1 2023.
- Cash and investments $21.6M at Mar 31, 2024, down from $29.8M at Dec 31, 2023; debt $14.6M.
- Late-breaking oral presentation of AHFIRM Phase 2b data accepted at EASL Congress 2024 in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/0000950170-24-058675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/drrx-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer